Measles virus vaccine live attenuated
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Measles virus vaccine live attenuated is a vaccine used to prevent Measles.
- Brand Names
- M-M-R II, Proquad
- Generic Name
- Measles virus vaccine live attenuated
- DrugBank Accession Number
- DB10315
- Background
Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Live attenuated measles virus (Schwartz strain)
- Measles vaccine (live)
- Measles virus live antigen
- Measles virus live antigen, A
- Measles virus strain enders' attenuated edmonston live (attenuated) antigen
- Measles virus strain enders' attenuated edmonston live antigen
- Measles virus vaccine live
- Measles virus vaccine live attenuated
- Measles Virus Vaccine Live, Enders' attenuated Edmonston strain
- Measles virus vaccine, inactivated
- Measles virus vaccine, live
- Measles virus vaccine, live, attenuated
- Measles virus vaccine,live attenuated
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Alemtuzumab. Altretamine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Altretamine. Amsacrine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Amsacrine. Anakinra The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Anakinra. Antilymphocyte immunoglobulin (horse) The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Antithymocyte immunoglobulin (rabbit) The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit). 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Measles Virus Vacc Live Att Freez Dried Inj Powder, for solution 1000 unit / vial Subcutaneous Iaf Biovac Inc. 1991-12-31 1997-08-20 Canada 
Measles Virus Vaccine Live Atten Dried Powder, for solution 1000 unit / .5 mL Subcutaneous Connaught Laboratories Ltd. 1982-12-31 2000-07-18 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image M-M-R II Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL) + Rubella virus vaccine (1000 TCID50/0.5mL) Powder, for solution Subcutaneous Merck Ltd. 1979-12-31 Not applicable Canada M-M-R II Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous A-S Medication Solutions 1971-04-21 Not applicable US 
M-M-R II Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Physicians Total Care, Inc. 1996-08-07 2012-06-30 US M-M-R II Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Merck Sharp & Dohme Corp. 1971-04-21 Not applicable US M-M-rvaxpro Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU 
M-M-rvaxpro Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU M-M-rvaxpro Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU M-M-rvaxpro Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Rubella virus vaccine (1000 TCID50) Injection, powder, for suspension Intramuscular; Subcutaneous Msd Vaccins 2021-02-10 Not applicable EU M-M-rvaxpro Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Rubella virus vaccine (1000 TCID50) Injection, powder, for suspension Intramuscular; Subcutaneous Msd Vaccins 2021-02-10 Not applicable EU M-M-rvaxpro Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- MFZ8I7277D
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention BCG Infection / Immune Responses / Vaccine Reaction 1 4 Completed Prevention Chickenpox / Hepatitis A / Mumps / Rubella / Rubeola 1 4 Completed Prevention Encephalitis, Japanese B / Mumps / Rubella / Rubeola 1 4 Completed Prevention Hepatitis A Virus 1 4 Completed Prevention Mumps / Rubella / Rubeola 2 3 Active Not Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Poliomyelitis / Tetanus 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Tetanus 1 3 Completed Prevention Bacterial Infections / Neisseria Meningitidis / Virus Diseases 2 3 Completed Prevention Bacterial Infections / Virus Diseases 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Subcutaneous Injection, powder, lyophilized, for suspension Subcutaneous Powder, for solution Subcutaneous Injection, powder, for suspension Intramuscular; Subcutaneous Injection, powder, lyophilized, for solution Subcutaneous Injection, powder, for solution 1000 CCID_50/0.5ml Powder, for solution Subcutaneous 1000 unit / vial Powder, for solution Subcutaneous 1000 unit / .5 mL Kit; liquid; powder, for solution Subcutaneous Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous Injection, powder, for solution Subcutaneous Kit; powder, for solution Intramuscular; Subcutaneous Injection, solution Intramuscular; Subcutaneous Injection, powder, for solution Intramuscular; Subcutaneous Injection Injection, powder, lyophilized, for suspension Intramuscular; Subcutaneous Injection, powder, lyophilized, for suspension Subcutaneous Injection Subcutaneous Solution Injection, powder, for solution Injection, suspension 1000 CCID_50/0.5ml Injection, powder, lyophilized, for suspension Powder - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 01, 2015 20:03 / Updated on July 24, 2021 14:58